Can-Fite BioPharma Ltd. (IL:CANF)
TASE:CANF
Want to see IL:CANF full AI Analyst Report?
CANF Stock Chart & Stats
732.30
>-0.01(-4.76%)
At close: 4:00 PM EST
732.30
>-0.01(-4.76%)
Day’s Range― - ―
52-Week Range433.10 - 4,200.00
Previous CloseN/A
Volume13.23M
Average Volume (3M)1.04M
Market Cap
₪20.05M
Enterprise Value8.54B
Total Cash (Recent Filing)₪6.46M
Total Debt (Recent Filing)₪90.00K
Price to Earnings (P/E)―
Beta-0.50
Next Earnings
Aug 27, 2026EPS Estimate
-72.18Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.00
Shares Outstanding4,285,093
10 Day Avg. Volume130,742
30 Day Avg. Volume1,039,800
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)2.77
Price to Sales (P/S)35.39
P/FCF Ratio-1.60
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.52
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Low Leverage / Balance-sheet FlexibilityVery low leverage reduces near-term financial risk and gives management flexibility to fund clinical programs or pursue partnerships without immediate debt pressure. This structural strength lengthens runway and supports strategic options over the next several quarters if cash burn moderates.
Focused Clinical-stage PipelineA concentrated small-molecule platform targeting the A3 adenosine receptor across inflammatory, liver, and oncologic indications is a structural advantage: expertise can be reused across indications, lowering marginal R&D cost per target and preserving upside if one program achieves regulatory success.
Improving Cash-burn Trend (2025 Vs 2024)A reduction in free cash burn in 2025 signals improving cost discipline or execution, which can meaningfully extend the company's financing runway. If sustained, this trend reduces near-term dilution risk and supports completion of pivotal trials or partnering discussions over the next 2–6 months.
Bears Say
Weak Revenue And Widening LossesPersistently tiny and declining revenue alongside growing operating losses undermines self-funding capacity and indicates the business model is not yet generating sustainable commercial cash flows. This structural deficit forces reliance on external capital and increases execution risk for long-term development plans.
Consistent Negative Cash GenerationChronic negative operating and free cash flow means the company cannot organically finance R&D or operations. Over time this requires recurring financing rounds or partnerships, raising dilution and creating execution uncertainty if capital markets or deal appetite weaken.
Negative ROE And Equity VolatilitySharply negative ROE and volatile equity levels reflect ongoing losses and past financing events, signaling shareholder dilution risk and limited capacity to invest in growth without further capital. This structural weakness pressures strategic flexibility and long-term investor confidence.
Can Fite Bio News
CANF FAQ
What was Can-Fite BioPharma Ltd.’s price range in the past 12 months?
Can-Fite BioPharma Ltd. lowest stock price was 433.10 and its highest was 4200.00 in the past 12 months.
What is Can-Fite BioPharma Ltd.’s market cap?
Can-Fite BioPharma Ltd.’s market cap is ₪20.05M.
When is Can-Fite BioPharma Ltd.’s upcoming earnings report date?
Can-Fite BioPharma Ltd.’s upcoming earnings report date is Aug 27, 2026 which is in 86 days.
How were Can-Fite BioPharma Ltd.’s earnings last quarter?
Can-Fite BioPharma Ltd. released its earnings results on Mar 26, 2026. The company reported -848.248 earnings per share for the quarter, missing the consensus estimate of -19.892 by -828.356.
Is Can-Fite BioPharma Ltd. overvalued?
According to Wall Street analysts Can-Fite BioPharma Ltd.’s price is currently Overvalued.
Does Can-Fite BioPharma Ltd. pay dividends?
Can-Fite BioPharma Ltd. does not currently pay dividends.
What is Can-Fite BioPharma Ltd.’s EPS estimate?
Can-Fite BioPharma Ltd.’s EPS estimate is -72.18.
How many shares outstanding does Can-Fite BioPharma Ltd. have?
Can-Fite BioPharma Ltd. has 4,285,093 shares outstanding.
What happened to Can-Fite BioPharma Ltd.’s price movement after its last earnings report?
Can-Fite BioPharma Ltd. reported an EPS of -848.248 in its last earnings report, missing expectations of -19.892. Following the earnings report the stock price went down -0.719%.
Which hedge fund is a major shareholder of Can-Fite BioPharma Ltd.?
Currently, no hedge funds are holding shares in IL:CANF
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Can-Fite BioPharma Ltd.
Can-Fite BioPharma Ltd., a clinical-stage biopharmaceutical company, develops small molecule therapeutic products for the treatment of cancer, liver inflammatory diseases, and erectile dysfunction. The company's lead drug candidate Piclidenoson, which has been completed Phase III clinical trial for the treatment of psoriasis; and Phase II clinical trial for the treatment of COVID-19. It also develops Namodenoson that is in Phase III clinical trial for the treatment of hepatocellular carcinoma, as well as in Phase IIb trial for the treatment of non-alcoholic steatohepatitis; and CF602, which is in pre-clinical trial for the treatment of erectile dysfunction. In addition, the company develops commercial predictive biomarker blood test kit for A3AR. Can-Fite BioPharma Ltd. has license and collaboration agreement with CMS Medical to develop, manufacture, and commercialize Piclidenoson and Namodenoson; and collaboration agreement with Univo Pharmaceuticals to identify and co-develop specific formulations of cannabis components for the treatment of cancer, inflammatory, autoimmune, and metabolic diseases. The company was formerly known as Can-Fite Technologies Ltd. and changed its name to Can-Fite BioPharma Ltd. in January 2001. Can-Fite BioPharma Ltd. was incorporated in 1994 and is headquartered in Petah Tikva, Israel.